Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies

Inclusion Criteria: * Stage II or III non-progressive disease Multiple Myeloma. * CLL/SLL, and low grade Hodgkin Lymphomas that are in a very good partial response or complete response with non-progressive disease. * ≤ 70 years old. * Eligible and willing HLA matched related donor. * Bilirubin \<2xULN. * ALT and AST \<3xULN. * LVEF \> 40%. * Creatinine Clearance \>40mL/min. * Pulmonary function DLCO corrected to ≥ 70%. * Minimum performance score of 70%. * Platelet count \>130 x103 micro L. * LDH ≤1.5xULN. * No proceeding co-morbid condition that significantly increases the risk of severe regimen related toxicity. * No uncontrolled infections. Exclusion Criteria: * Age \>70 years old. * Performance status \<70%. * Uncontrolled infections or is HIV positive * Prior malignancies that are felt to have a \<80% probability of being cured. * Pregnant, breastfeeding, or refuse to use contraceptive techniques during and for 12 months following transplant. * Prior Allograft * History of rapidly growing disease at diagnosis or at any progression or have MDS. * No eligible and willing HLA matched donor.